Published in Arthritis Rheum on December 01, 2004
Understanding the epidemiology and progression of systemic lupus erythematosus. Semin Arthritis Rheum (2009) 2.32
Atherosclerotic vascular events in a multinational inception cohort of systemic lupus erythematosus. Arthritis Care Res (Hoboken) (2010) 1.84
Oxidized LDL: diversity, patterns of recognition, and pathophysiology. Antioxid Redox Signal (2010) 1.47
Risk and protective factors for thrombosis in systemic lupus erythematosus: results from a large, multi-ethnic cohort. Ann Rheum Dis (2008) 1.38
Excess atherosclerosis in systemic lupus erythematosus,-A matter of renal involvement: Case control study of 281 SLE patients and 281 individually matched population controls. PLoS One (2017) 1.37
Premature atherosclerosis in pediatric systemic lupus erythematosus: risk factors for increased carotid intima-media thickness in the atherosclerosis prevention in pediatric lupus erythematosus cohort. Arthritis Rheum (2009) 1.37
Predictors of the first cardiovascular event in patients with systemic lupus erythematosus - a prospective cohort study. Arthritis Res Ther (2009) 1.29
Incidence of and risk factors for adverse cardiovascular events among patients with systemic lupus erythematosus. Am J Epidemiol (2012) 1.27
Prevalence and burden of pediatric-onset systemic lupus erythematosus. Nat Rev Rheumatol (2010) 1.23
Cardiovascular co-morbidity in rheumatic diseases. Vasc Health Risk Manag (2008) 1.16
Risk factors for cardiovascular mortality in patients with systemic lupus erythematosus, a prospective cohort study. Arthritis Res Ther (2012) 1.11
Accelerated atherosclerosis in patients with SLE--mechanisms and management. Nat Rev Rheumatol (2012) 1.08
Cardiovascular disease in systemic lupus erythematosus: the role of traditional and lupus related risk factors. Curr Cardiol Rev (2008) 1.02
Systemic lupus erythematosus and cardiovascular disease: prediction and potential for therapeutic intervention. Expert Rev Clin Immunol (2011) 0.96
Laboratory markers of cardiovascular risk in pediatric SLE: the APPLE baseline cohort. Lupus (2010) 0.92
Predictors of progression in atherosclerosis over 2 years in systemic lupus erythematosus. Rheumatology (Oxford) (2011) 0.90
Predictors of cardiovascular damage in patients with systemic lupus erythematosus: data from LUMINA (LXVIII), a multiethnic US cohort. Rheumatology (Oxford) (2009) 0.89
Cardiovascular and disease-related predictors of depression in systemic lupus erythematosus. Arthritis Care Res (Hoboken) (2011) 0.89
Cardiovascular disease in rheumatoid arthritis: a systematic literature review in latin america. Arthritis (2012) 0.89
Cardiovascular risk in pediatric-onset rheumatological diseases. Arthritis Res Ther (2013) 0.88
Subclinical atherosclerosis and impaired bone health in patients with primary Sjogren's syndrome: prevalence, clinical and laboratory associations. Arthritis Res Ther (2015) 0.88
Management of Neuropsychiatric Systemic Lupus Erythematosus: Current Approaches and Future Perspectives. Drugs (2016) 0.88
High-sensitivity C-reactive protein, disease activity, and cardiovascular risk factors in systemic lupus erythematosus. Arthritis Care Res (Hoboken) (2013) 0.87
Thrombosis in systemic lupus erythematosus: a review article. ISRN Rheumatol (2012) 0.87
Factors associated with metabolic syndrome in patients with systemic lupus erythematosus from Puerto Rico. Lupus (2008) 0.87
Systemic lupus erythematosus in a multiethnic US cohort (LUMINA): LXI. Value of C-reactive protein as a marker of disease activity and damage. J Rheumatol (2008) 0.87
Factors associated with arterial vascular events in PROFILE: a Multiethnic Lupus Cohort. Lupus (2009) 0.85
Management of cardiovascular complications in systemic lupus erythematosus. Int J Clin Rheumtol (2010) 0.85
Genetic risk factors for thrombosis in systemic lupus erythematosus. J Rheumatol (2012) 0.85
Vitamin D deficiency does not predict progression of coronary artery calcium, carotid intima-media thickness or high-sensitivity C-reactive protein in systemic lupus erythematosus. Rheumatology (Oxford) (2013) 0.84
Genetic determinants of basal C-reactive protein expression in Filipino systemic lupus erythematosus families. Genes Immun (2008) 0.84
Prospective cohort studies on risk factors for cardiovascular events in systemic lupus erythematosus: a major challenge. Arthritis Res Ther (2010) 0.83
Atherosclerosis in systemic lupus erythematosus. J Cardiovasc Pharmacol (2013) 0.83
Antiphospholipid syndrome and the brain in pediatric and adult patients. Lupus (2010) 0.83
Cardiovascular involvement in autoimmune diseases. Biomed Res Int (2014) 0.82
Atherosclerotic plaques occur in absence of intima-media thickening in both systemic sclerosis and systemic lupus erythematosus: a duplexsonography study of carotid and femoral arteries and follow-up for cardiovascular events. Arthritis Res Ther (2014) 0.81
Factor V Leiden and thrombosis in patients with systemic lupus erythematosus: a meta-analysis. Genes Immun (2009) 0.80
A polymorphism in TLR2 is associated with arterial thrombosis in a multiethnic population of patients with systemic lupus erythematosus. Arthritis Rheumatol (2014) 0.80
Risk of Peripheral Arterial Occlusive Disease in Patients With Systemic Lupus Erythematosus: A Nationwide Population-Based Cohort Study. Medicine (Baltimore) (2015) 0.80
Cardiovascular disease in latin american patients with systemic lupus erythematosus: a cross-sectional study and a systematic review. Autoimmune Dis (2013) 0.80
Cardiovascular Events in Systemic Lupus Erythematosus: A Nationwide Study in Spain From the RELESSER Registry. Medicine (Baltimore) (2015) 0.80
Frequency of established cardiovascular disease and its risk factors in Chinese patients with systemic lupus erythematosus. Clin Rheumatol (2011) 0.79
African-American and Hispanic ethnicities, renal involvement and obesity predispose to hypertension in systemic lupus erythematosus: results from LUMINA, a multiethnic cohort (LUMINAXLV). Ann Rheum Dis (2006) 0.79
Antiphospholipid antibodies predict imminent vascular events independently from other risk factors in a prospective cohort. Thromb Haemost (2009) 0.79
The clinical significance of antiphospholipid antibodies in systemic lupus erythematosus. Eur J Rheumatol (2015) 0.79
The coexistence of antiphospholipid syndrome and systemic lupus erythematosus in Colombians. PLoS One (2014) 0.78
Low socioeconomic status is associated with cardiovascular risk factors and outcomes in systemic lupus erythematosus. J Rheumatol (2012) 0.78
Von Willebrand factor, red cell fragmentation, and disease activity in systemic lupus erythematosus. HSS J (2008) 0.78
Nephritis and the risk of acute myocardial infarction in patients with systemic lupus erythematosus. Clin Exp Rheumatol (2010) 0.77
The relationship between race, cigarette smoking and carotid intimal medial thickness in systemic lupus erythematosus. Lupus (2009) 0.77
Lupus nephritis and Raynaud's phenomenon are significant risk factors for vascular thrombosis in SLE patients with positive antiphospholipid antibodies. Clin Rheumatol (2007) 0.77
Survival rates and risk factors for mortality in systemic lupus erythematosus patients in a Chinese center. Clin Rheumatol (2014) 0.76
Accelerated atherosclerosis in SLE: mechanisms and prevention approaches. Int J Clin Rheumtol (2012) 0.76
Progression of carotid atherosclerosis in patients with systemic lupus erythematosus. Clin Rheumatol (2013) 0.76
Anti-phospholipid Antibodies and Smoking: An Overview. Clin Rev Allergy Immunol (2017) 0.75
Serum Resistin Level and Progression of Atherosclerosis during Glucocorticoid Therapy for Systemic Autoimmune Diseases. Metabolites (2016) 0.75
Prevalence and associated factors of resting electrocardiogram abnormalities among systemic lupus erythematosus patients without cardiovascular disease. Arthritis Res Ther (2017) 0.75
Short-term perioperative all-cause mortality and cardiovascular events in women with systemic lupus erythematosus. Arthritis Care Res (Hoboken) (2013) 0.75
Cardiovascular disease in immune-mediated inflammatory diseases: A cross-sectional analysis of 6 cohorts. Medicine (Baltimore) (2017) 0.75
The risk benefit ratio of glucocorticoids in SLE: have things changed over the past 40 years? Curr Treatm Opt Rheumatol (2017) 0.75
Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I. Arthritis Rheum (2008) 13.08
Association scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variants. Nat Genet (2007) 12.62
Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum (2012) 6.85
2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative. Arthritis Rheum (2013) 5.99
A large-scale replication study identifies TNIP1, PRDM1, JAZF1, UHRF1BP1 and IL10 as risk loci for systemic lupus erythematosus. Nat Genet (2009) 5.75
Efficacy of remission-induction regimens for ANCA-associated vasculitis. N Engl J Med (2013) 5.67
Interaction between ERAP1 and HLA-B27 in ankylosing spondylitis implicates peptide handling in the mechanism for HLA-B27 in disease susceptibility. Nat Genet (2011) 5.56
Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum (2002) 5.12
Headache in systemic lupus erythematosus: results from a prospective, international inception cohort study. Arthritis Rheum (2013) 4.02
International recommendations for the assessment of autoantibodies to cellular antigens referred to as anti-nuclear antibodies. Ann Rheum Dis (2013) 3.99
Proteome-wide analysis and CXCL4 as a biomarker in systemic sclerosis. N Engl J Med (2013) 3.81
Genome-wide association study of ankylosing spondylitis identifies non-MHC susceptibility loci. Nat Genet (2010) 3.58
A multicenter, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis. Arthritis Rheum (2002) 3.55
Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum (2006) 3.51
Human papilloma virus vaccine and primary ovarian failure: another facet of the autoimmune/inflammatory syndrome induced by adjuvants. Am J Reprod Immunol (2013) 3.42
Pathogenesis and natural history of osteonecrosis. Semin Arthritis Rheum (2002) 3.30
Autoantibody explosion in systemic lupus erythematosus: more than 100 different antibodies found in SLE patients. Semin Arthritis Rheum (2004) 3.23
2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative. Ann Rheum Dis (2013) 3.11
Gene and pathway-based second-wave analysis of genome-wide association studies. Eur J Hum Genet (2010) 3.03
The effect of combined estrogen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus: a randomized trial. Ann Intern Med (2005) 2.92
Vitamin D effects on musculoskeletal health, immunity, autoimmunity, cardiovascular disease, cancer, fertility, pregnancy, dementia and mortality-a review of recent evidence. Autoimmun Rev (2013) 2.87
Identification of multiple risk variants for ankylosing spondylitis through high-density genotyping of immune-related loci. Nat Genet (2013) 2.87
HIV and autoimmunity. Autoimmun Rev (2002) 2.83
Vitamin D and autoimmunity: new aetiological and therapeutic considerations. Ann Rheum Dis (2007) 2.76
A comparison of the abilities of nine scoring algorithms in predicting mortality. J Trauma (2002) 2.70
Can high-risk older drivers be identified through performance-based measures in a Department of Motor Vehicles setting? J Am Geriatr Soc (2006) 2.67
Impact of cataract surgery on motor vehicle crash involvement by older adults. JAMA (2002) 2.67
Timed instrumental activities of daily living tasks: relationship to cognitive function and everyday performance assessments in older adults. Gerontology (2002) 2.61
Identifying risk for massive transfusion in the relatively normotensive patient: utility of the prehospital shock index. J Trauma (2011) 2.59
Measurement of electrical skin impedance of dermal-visceral zones as a diagnostic tool for inner organ pathologies: a blinded preliminary evaluation of a new technique. Isr Med Assoc J (2005) 2.57
Association of a functional variant downstream of TNFAIP3 with systemic lupus erythematosus. Nat Genet (2011) 2.54
Association between depression and functional vision loss in persons 20 years of age or older in the United States, NHANES 2005-2008. JAMA Ophthalmol (2013) 2.52
Protective effect of hydroxychloroquine on renal damage in patients with lupus nephritis: LXV, data from a multiethnic US cohort. Arthritis Rheum (2009) 2.50
Effects of tobacco smoke on immunity, inflammation and autoimmunity. J Autoimmun (2009) 2.49
Association of variants at 1q32 and STAT3 with ankylosing spondylitis suggests genetic overlap with Crohn's disease. PLoS Genet (2010) 2.44
Sheathotomy to decompress branch retinal vein occlusion: a matched control study. Ophthalmology (2004) 2.43
Electronic monitoring of oral therapies in ethnically diverse and economically disadvantaged patients with rheumatoid arthritis: consequences of low adherence. Arthritis Rheum (2013) 2.42
The impact of tumor necrosis factor α inhibitors on radiographic progression in ankylosing spondylitis. Arthritis Rheum (2013) 2.40
Vitamin D and musculoskeletal health, cardiovascular disease, autoimmunity and cancer: Recommendations for clinical practice. Autoimmun Rev (2010) 2.38
Health-related quality of life and psychosocial characteristics of patients with benign essential blepharospasm. Arch Ophthalmol (2006) 2.36
Understanding the epidemiology and progression of systemic lupus erythematosus. Semin Arthritis Rheum (2009) 2.32
Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial. Ann Rheum Dis (2010) 2.30
A multiethnic, multicenter cohort of patients with systemic lupus erythematosus (SLE) as a model for the study of ethnic disparities in SLE. Arthritis Rheum (2007) 2.24
IgA1-secreting cell lines from patients with IgA nephropathy produce aberrantly glycosylated IgA1. J Clin Invest (2008) 2.15
The concept of axial spondyloarthritis: joint statement of the spondyloarthritis research and treatment network and the Assessment of SpondyloArthritis international Society in response to the US Food and Drug Administration's comments and concerns. Arthritis Rheumatol (2014) 2.14
Vaccination may be associated with autoimmune diseases. Isr Med Assoc J (2004) 2.14
Human chorioretinal layer thicknesses measured in macula-wide, high-resolution histologic sections. Invest Ophthalmol Vis Sci (2011) 2.13
The HLA-DRB1 shared epitope is associated with susceptibility to rheumatoid arthritis in African Americans through European genetic admixture. Arthritis Rheum (2008) 2.13
Kidney function influences warfarin responsiveness and hemorrhagic complications. J Am Soc Nephrol (2009) 2.13
Negative pressure wound therapy after severe open fractures: a prospective randomized study. J Orthop Trauma (2009) 2.10
Cognitive training decreases motor vehicle collision involvement of older drivers. J Am Geriatr Soc (2010) 2.08
Age of transfused blood: an independent predictor of mortality despite universal leukoreduction. J Trauma (2008) 2.07
Discrimination between glaucomatous and nonglaucomatous eyes using quantitative imaging devices and subjective optic nerve head assessment. Invest Ophthalmol Vis Sci (2006) 2.05
The Lancet against Israel. Isr Med Assoc J (2013) 2.03
The relationship of blood product ratio to mortality: survival benefit or survival bias? J Trauma (2009) 2.03
Intensive lipid-lowering therapy: obvious benefits, possible risks. Isr Med Assoc J (2006) 2.02
Association between side-impact airbag deployment and risk of injury: A matched cohort study using the CIREN and the NASS-CDS. J Trauma Acute Care Surg (2012) 2.01
Influence of CYP2C9 and VKORC1 on warfarin dose, anticoagulation attainment and maintenance among European-Americans and African-Americans. Pharmacogenomics (2008) 1.89
Lipid peroxidation is enhanced in patients with systemic lupus erythematosus and is associated with arterial and renal disease manifestations. Arthritis Rheum (2005) 1.89
Major histocompatibility complex (MHC) class II alleles, haplotypes and epitopes which confer susceptibility or protection in systemic sclerosis: analyses in 1300 Caucasian, African-American and Hispanic cases and 1000 controls. Ann Rheum Dis (2009) 1.84
Epidemiology and sociodemographics of systemic lupus erythematosus and lupus nephritis among US adults with Medicaid coverage, 2000-2004. Arthritis Rheum (2013) 1.80
Vision and driving. Vision Res (2010) 1.80
The role of inflammatory cytokines in the pathogenesis of systemic lupus erythematosus-related atherosclerosis: a novel target for treatment? J Rheumatol (2006) 1.79
Trajectories of life-space mobility after hospitalization. Ann Intern Med (2009) 1.78
Catastrophic antiphospholipid syndrome (CAPS): descriptive analysis of a series of 280 patients from the "CAPS Registry". J Autoimmun (2009) 1.78
Anti-inflammatory and immunosuppressive drugs and reproduction. Arthritis Res Ther (2006) 1.78
On-road driving performance by persons with hemianopia and quadrantanopia. Invest Ophthalmol Vis Sci (2008) 1.74
Transfusions in the less severely injured: does age of transfused blood affect outcomes? J Trauma (2008) 1.73
Association between vaccination and Guillain-Barré syndrome. Lancet Infect Dis (2013) 1.69
Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: data from LUMINA, a multiethnic US cohort (LUMINA L). Ann Rheum Dis (2007) 1.69
Vitamin D insufficiency in a sunny environment: a demographic and seasonal analysis. Isr Med Assoc J (2010) 1.68
Trends in the incidence, demographics, and outcomes of end-stage renal disease due to lupus nephritis in the US from 1995 to 2006. Arthritis Rheum (2011) 1.68
Defining and analyzing geoepidemiology and human autoimmunity. J Autoimmun (2010) 1.67
Matrix metalloproteinase-9 and autoimmune diseases. J Clin Immunol (2006) 1.66
Systemic lupus erythematosus in three ethnic groups: XVI. Association of hydroxychloroquine use with reduced risk of damage accrual. Arthritis Rheum (2005) 1.64
Fatal work-related inhalation of harmful substances in the United States. Chest (2002) 1.64
Klinefelter's syndrome (47,XXY) in male systemic lupus erythematosus patients: support for the notion of a gene-dose effect from the X chromosome. Arthritis Rheum (2008) 1.64